Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-03T00:15:43.850Z.
Calculation as of: 2026-10-03T00:15:43.850Z.
Quote observation: 2026-10-02T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2836fcafd5945f83081e0b78d1a6da2eca1ef0bf3f8332e90753a26548b70525
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Intellia Therapeutics, Inc.
Market Cap
$1.71B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.74B
EV/EBITDA Ratio
4.46x
TTM Avg
6.95x
3Y Avg
36.54x
5Y Avg
27.67x
Market Cap
$1.90B
EV/EBITDA Ratio
31.92x
TTM Avg
35.11x
3Y Avg
121.42x
5Y Avg
105.31x
Market Cap
$2.16B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
EV/EBITDA Ratio
12.45x
TTM Avg
29.15x
3Y Avg
193.67x
5Y Avg
193.67x
Market Cap
$2.76B
EV/EBITDA Ratio
26.71x
TTM Avg
36.01x
3Y Avg
85.66x
5Y Avg
85.66x
Market Cap
$474.59M
EV/EBITDA Ratio
N/A
TTM Avg
74.72x
3Y Avg
37.71x
5Y Avg
26.88x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | $1.71B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 4.46x | 6.95x | 36.54x | 27.67x |
| Fortrea Holdings Inc. (FTRE)vs › | $1.90B | 31.92x | 35.11x | 121.42x | 105.31x |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 12.45x | 29.15x | 193.67x | 193.67x |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 26.71x | 36.01x | 85.66x | 85.66x |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | N/A | 74.72x | 37.71x | 26.88x |
| NRC Health (NRC)vs › | $458.62M | 23.34x | 16.31x | 15.05x | 16.68x |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
